Liquid Biopsy for Cancer in Hyderabad

Quick answer: A liquid biopsy is a blood test that detects tumour DNA (and other cancer-derived material) circulating in the bloodstream, so cancer can be genotyped and monitored without cutting tissue. It is used when a tumour is hard to biopsy, to genotype quickly, and to track a cancer's response and resistance over time. At Indian OncoCare in Hyderabad, liquid-biopsy results are interpreted and applied personally by Dr. Harish Kancharla, DM (Medical Oncology, AIIMS New Delhi), Senior Consultant – Medical Oncology & Hemato-Oncology at Yashoda Hospitals, Somajiguda, Hyderabad, with consultations in person and online for patients across India and abroad.

• What it is: a blood-based test that reads circulating tumour DNA (ctDNA) shed by the cancer.
• Minimally invasive: a simple blood draw — no surgical biopsy, and easily repeatable.
• What it finds: mutations, gene fusions and other markers that guide targeted therapy and immunotherapy.
• When it helps most: limited or hard-to-reach tissue, rapid genotyping, and monitoring over time.
• Important limit: a negative liquid biopsy does not rule cancer out — tissue testing remains the reference in many situations.

A liquid biopsy analyses tumour-derived material — most often circulating tumour DNA (ctDNA) — found in a sample of your blood. As a tumour grows, it sheds tiny fragments of DNA into the bloodstream; a liquid biopsy captures and reads them. In effect, it lets your oncologist study the cancer's genetics from a blood draw rather than a surgical sample.

It is a key tool within molecular oncology, feeding directly into a precision-medicine plan — but its defining advantage is that it is minimally invasive and can be repeated as often as clinically useful.

Tumour marker tests measure proteins or other substances in the blood, such as CA-125 or CEA. They can be useful for monitoring some cancers, but they do not usually show the cancer’s genetic changes. A liquid biopsy test looks for circulating tumour DNA and can report specific mutations, fusions or resistance changes. In other words, a tumour marker test may indicate that something is happening; a liquid biopsy test may help explain what can be done about it. Your oncologist may use both, depending on the cancer type and the question being asked.

From a blood sample, a liquid biopsy can identify:

• Gene mutations — such as EGFR, KRAS or BRAF.
• Gene fusions and rearrangements — such as ALK or ROS1.
• Resistance mutations — new changes that emerge when a cancer stops responding to treatment (for example, EGFR T790M in lung cancer).
• Other genomic markers — depending on the panel used, features that help select systemic therapy.

These findings map to the same actions as tissue testing: a driver mutation may point to a matched targeted therapy, while other markers may guide immunotherapy or confirm that standard chemotherapy is the best route.

A liquid biopsy is especially valuable in specific situations:

• When tissue is limited or hard to obtain — for tumours in locations that are risky or difficult to biopsy, or when an earlier sample is exhausted.
• For rapid, tissue-sparing genotyping — sometimes results return faster than a repeat tissue procedure allows.
• To monitor response — repeat testing can show whether a treatment is working at the molecular level.
• To detect resistance early — at progression, a liquid biopsy can reveal why a therapy has stopped working and open a new line of treatment.

Some newer applications — such as detecting minimal (molecular) residual disease after curative treatment, and multi-cancer early detection — are advancing rapidly but remain emerging and are used selectively. Your oncologist advises where a liquid biopsy genuinely adds value in your case.

Liquid biopsy is most established in advanced solid tumours, especially non-small cell lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, pancreatic cancer and gastro-oesophageal cancers. In these cancers, it can help identify targets for treatment or detect resistance. Use in other cancers — including some lymphomas and sarcomas — is growing but depends on the tumour type, the stage and the laboratory panel. It is not a routine screening test for all cancers. For some tumour types, tissue testing remains the only reliable way to get the information needed.

They are complementary, not competing. A tissue biopsy remains the reference standard for confirming a diagnosis under the microscope and for many molecular tests. A liquid biopsy adds a minimally invasive, repeatable window into the cancer's genetics — invaluable when tissue is scarce or when the cancer needs tracking over time. In practice, the two are often used together, and understanding your original biopsy report helps put liquid-biopsy results in context.

Accuracy depends on the cancer, its stage, the amount of tumour DNA shed into the blood, and the test used. In advanced cancers with a high tumour burden, a liquid biopsy can be quite sensitive for the mutations it is designed to find. In early-stage cancer or after treatment, levels of circulating tumour DNA may be low, so a negative result can be less informative. Results are usually reported with a variant allele fraction, which gives a sense of how much tumour DNA was seen. Because no single test answers every question, your oncologist may compare liquid biopsy findings with your imaging, tissue report and clinical course. Understanding your original tissue biopsy report can help you follow this comparison: Understanding Your Biopsy Report: A Plain-English Guide for Patients.

The test itself is simply a blood draw — no anaesthesia, no procedure. The sample is processed to isolate and sequence circulating tumour DNA. Turnaround varies by the panel used, but results are typically available within days to a couple of weeks. Because it is just a blood test, it can be repeated at intervals to follow the cancer's behaviour without additional procedures.

Preparation is usually simple. Most patients do not need to fast, and you can generally take your regular medicines. Tell your oncology team about blood thinners, recent blood transfusions, active infection or any treatment you have had in the last few weeks, because these can sometimes affect the sample. A single blood draw is usually enough. The sample is then sent to a molecular laboratory, where circulating tumour DNA is isolated and tested using methods such as next-generation sequencing or digital PCR. You do not need anaesthesia and there is no recovery time. If a repeat test is planned, it is often timed around a scan or a change in treatment.

Being honest about limits matters. A liquid biopsy depends on the tumour shedding enough DNA into the blood — so a negative result does not necessarily mean a mutation is absent; it may simply be below the level of detection. For that reason, tissue testing is still preferred in many situations, and a negative liquid biopsy is often followed by tissue analysis. A liquid biopsy also cannot replace tissue for the initial histological diagnosis. This is exactly why expert interpretation — rather than a report read in isolation — is essential.

A liquid biopsy cannot replace every part of a tissue biopsy. It cannot confirm the cancer’s histological type under the microscope, and it generally cannot measure protein markers such as PD-L1, HER2 or hormone receptors, which need tissue. It does not show where the cancer is, how large it is, or whether it has spread — imaging does that. It cannot rule cancer out: a negative result may mean the tumour is not shedding enough DNA into the blood. It is not yet a routine screening test for people without a cancer diagnosis. And it cannot choose treatment on its own; the result has to be interpreted alongside your full clinical picture. This is why liquid biopsy is usually described as complementary to tissue biopsy, not a replacement.

Each finding points to an action: a driver mutation may indicate a matched targeted therapy; resistance mutations at progression may switch you to a new line of treatment; and monitoring results may confirm a therapy is working or prompt an earlier change. Where a hereditary risk is suspected, separate cancer genetic testing may also be advised. If a plan has been made elsewhere, a second opinion that considers whether a liquid biopsy is warranted can be worthwhile.

In Hyderabad, liquid biopsy testing is usually arranged through your treating oncologist rather than by walking into a laboratory directly. The process generally works like this:

1. Ask your oncologist whether it is appropriate. Not every cancer or every stage needs a liquid biopsy. The decision depends on the cancer type, what information is missing, and whether tissue testing is possible.
2. Get a clear test request. The request should state the cancer type, the question being asked (for example, looking for an EGFR mutation or resistance change), and any prior tissue results. This helps the laboratory choose the right panel.
3. Use an accredited molecular laboratory. Your oncologist can suggest laboratories that offer validated liquid biopsy panels. If you are comparing options, ask about the genes covered, the technology used, and how the report is structured.
4. Arrange the blood draw. In most cases, a blood sample can be collected at a hospital, day-care centre or laboratory collection point. No special preparation is usually needed.
5. Plan for interpretation. The report should be reviewed by your oncologist together with your imaging and tissue reports. A raw report without clinical context can be misleading.

If you are outside Hyderabad or India, a common first step is an online consultation and report review, followed by testing and treatment in person if needed. 

A blood-based test is particularly convenient for patients at a distance:

• Start online. Overseas and out-of-state patients usually begin with an online consultation and report review before travelling.
• Coordinated testing. Sample collection, testing and treatment continue in person at Yashoda Hospitals, Somajiguda.
• Practical support. Our international patients service assists with report review, estimates and coordination, and patient support resources help you and your family prepare for each step. For cost context, see the cost of cancer treatment in India and our financial guidance page.

A liquid-biopsy result is only useful when it is interpreted correctly and acted on in context. Your care is led personally by Dr. Harish Kancharla — DM (Medical Oncology), BRAIRCH, AIIMS New Delhi; MD (Internal Medicine), PGIMER Chandigarh; Telangana State Medical Council Reg. No. 77186 — who reads the molecular findings alongside your full clinical picture and translates them into a practical plan, delivered through Yashoda Hospitals, Somajiguda, Hyderabad. What this means for you:

• Expert interpretation, including knowing when a liquid biopsy will and will not help.
• One consultant across the journey, from testing through treatment and follow-up.
• The full diagnostic toolkit — molecular oncology, liquid biopsy and cancer genetic testing — feeding directly into precision medicine.
• Support for the whole family, including practical and financial guidance.

Is a liquid biopsy just a blood test? Yes. It analyses tumour DNA circulating in a blood sample — no surgical procedure — and can be repeated as needed.

Can a liquid biopsy replace a tissue biopsy? Not entirely. Tissue remains the reference for diagnosis and many tests; a liquid biopsy complements it, and a negative result does not rule a mutation out.

When is a liquid biopsy most useful? When tissue is limited or hard to obtain, for rapid genotyping, to monitor response, and to detect resistance when a treatment stops working.

Can international and out-of-state patients access this? Yes. Many begin with an online consultation and report review before travelling, then continue in person at Yashoda Hospitals, Somajiguda.

Who interprets the results? Dr. Harish Kancharla, DM (Medical Oncology, AIIMS New Delhi), interprets the findings and plans treatment personally.

Is a liquid biopsy test available in India? Yes. Molecular laboratories in India offer liquid biopsy panels, but availability varies by city and by the specific test. Your oncologist can advise what is available and appropriate for your cancer.

How much does a liquid biopsy test cost in India? Costs depend on the panel size, the technology and the laboratory. Ask your treating team or the laboratory for a written estimate before testing.

Can I do a liquid biopsy test near me? The blood draw itself can often be done locally, but the sample must be processed at a molecular laboratory with the right platform. Your oncologist can help coordinate this.

Do I need a liquid biopsy if I already had a tissue biopsy? Not always. If your tissue test already gives the answers needed, a liquid biopsy may not add anything. It is most useful when tissue is insufficient, a repeat biopsy is difficult, or monitoring over time is needed.

Can a liquid biopsy be repeated? Yes. Because it is a blood test, it can be repeated at intervals to track response or resistance, as advised by your oncologist.

Molecular Oncology · Precision Medicine · Cancer Genetic Testing · Targeted Therapy · Immunotherapy · Chemotherapy · Day Care Chemotherapy · Second Opinion · Lung Cancer · Colorectal Cancer · Breast Cancer · Ovarian Cancer · Lymphoma · Head & Neck Cancer · Stomach Cancer · Liver Cancer · Pancreatic Cancer · Leukemia · Multiple Myeloma · Bone Marrow Transplant

• U.S. National Cancer Institute — Liquid Biopsy (definition)
• U.S. National Cancer Institute — Biomarker Testing for Cancer Treatment
• American Cancer Society — Tumor Marker Tests
• ASCO / Cancer.Net — Biomarker Testing for Cancer
• European Society for Medical Oncology (ESMO) — Patient Guides

Medically reviewed by Dr. Harish Kancharla, DM (Medical Oncology, AIIMS New Delhi), MD (Internal Medicine, PGIMER Chandigarh), Senior Consultant – Medical Oncology & Hemato-Oncology, Yashoda Hospitals, Somajiguda, Hyderabad. Telangana State Medical Council Reg. No. 77186. Last reviewed: August 2026.

This page is general information about liquid biopsy testing and is not a substitute for personal medical advice. Treatment decisions must be made with a qualified oncologist who has reviewed your reports.